NICE rejects arthritis drug in draft advice

Golimumab has not been recommended for use in treating psoriatic arthritis, under draft guidance issued by NICE.

Psoriatic arthritis  (Photograph: SPL)
Psoriatic arthritis (Photograph: SPL)

The drug is licensed for use alone, or in combination with methotrexate, for active and progressive psoriatic arthritis in adult patients when previous therapy has been inadequate.

It is also licensed for limited use in the treatment of rheumatoid arthritis and ankylosing spondylitis.

NICE has made the recommendation because research shows golimumab is not more cost-effective than other available options. A spokesman said: 'NICE recommends adalimumab, etanercept and infliximab for the treatment of psoriatic arthritis in people with peripheral arthritis. The cost-effectiveness analyses found that golimumab was not the most cost-effective of the available options currently recommended by NICE.'

A secondary reason for the advice was uncertainty about possible side-effects of the drug, as a long-term follow-up on adverse outcomes is ongoing.

The spokesman added that economic modelling based on evidence about golimumab had shown the drug may be less cost-effective than etanercept, and 'could not be considered a good use of NHS resources'.

The drug's manufacturer MSD said: 'MSD strongly believes that any restrictions on access to this treatment would inhibit patient choice for the treatment of this disabling and chronic disease.'

The draft guidance is open to consultation.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Government 'ramping up' plans for COVID-19 booster jabs in autumn

Government 'ramping up' plans for COVID-19 booster jabs in autumn

The government is 'ramping up' plans for an autumn booster campaign that could see...

Fitness to practise cases may remain unresolved after COVID-19 disruption

Fitness to practise cases may remain unresolved after COVID-19 disruption

Some fitness to practise cases may ‘prove impossible to resolve’ following delays...

GMC survey to assess COVID impact on GP training

GMC survey to assess COVID impact on GP training

Disruption to training for thousands of GPs during the COVID-19 pandemic will be...

GPs demand government review into unprecedented demand on general practice

GPs demand government review into unprecedented demand on general practice

GPs have demanded an urgent review into soaring demand on general practice, after...

Vaccination sites to offer Pfizer or Moderna vaccine to pregnant women

Vaccination sites to offer Pfizer or Moderna vaccine to pregnant women

Vaccination sites have been told to offer pregnant women the Moderna or Pfizer COVID-19...

Fifth of adults fully vaccinated against COVID-19 as UK hits 10m second dose milestone

Fifth of adults fully vaccinated against COVID-19 as UK hits 10m second dose milestone

More than 10m people UK-wide have received both doses of COVID-19 vaccine - just...